March 30 (Reuters) - Cyclopharm Ltd (CYC) :
- ENTERED FINAL REVIEW PROCESS FOR ATTAINING USFDA APPROVAL TO COMMENCE COMMERCIAL SALES OF TECHNEGAS IN US MARKET IN 2023
- EXPECTS TO MAINTAIN ACTIVE DIALOGUE WITH USFDA IN SIX-MONTH REVIEW PERIOD
- SALES OF TECHNEGAS IN US ARE EXPECTED TO COMMENCE IN LATE 2023
News: CYC Cyclopharm Says Sales Of Technegas In U.S. Expected To Commence In Late 2023
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
93.0¢ |
Change
0.020(2.20%) |
Mkt cap ! $103.3M | |||
| Open | High | Low | Value | Volume |
| 92.5¢ | 95.0¢ | 90.5¢ | $82.50K | 90.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 4766 | 1 |
View Market Depth
| Last trade - 15.59pm 27/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |